Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Milei Threatens Falkland Oil Firms With Sanctions 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Anthropic IPO Marketing Expected to Start in Mid-October 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Add as a preferred source on Google
SAN FRANCISCO, Feb. 28, 2018 -- Hagens Berman Sobol Shapiro LLP reminds investors in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) of the April 10, 2018 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired Synergy securities between September 5, 2017 and November 14, 2017 and suffered losses, contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SGYP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
The Complaint charges Defendants with making false or misleading statements about the terms of a $300 million senior secured loan to Synergy from CRG Partners III L.P. More specifically, the Complaint charges Defendants falsely described this financing as non-dilutive to shareholders on September 5, 2017.
When Synergy filed the CRG loan agreement with the SEC on November 9, 2017, it revealed that the financing would likely be dilutive to shareholders. This news drove the price of Synergy shares down $0.25, or about 8.4%, to close at $2.72 on November 10, 2017.
On November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares. This news drove the price of Synergy shares down $0.14, or about 6.9% to close at $1.89 on November 15, 2017.
“We’re focused on the defendants’ statements about the financing’s impact on equity investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
